viewBiocept Inc

Biocept reveals double-digit revenue jump and new Target Selector molecular assay kit

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive how the California-based company saw revenue jump by double-digits in its fiscal first quarter despite headwinds from the coronavirus pandemic.

What's more, Nall says the developer of liquid biopsy tests has released a new Target Selector molecular assay research-use-only kit for clients to use in their own laboratories. The kit will help to detect BRAF mutations, among the most frequently evaluated biomarkers across many solid tumor cancers, including lung cancer and melanoma.

Quick facts: Biocept Inc

Price: 0.6996 USD

Market: NASDAQ
Market Cap: $91.72 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...



Jubilee Metals CEO welcomes 54% growth in first half operational earnings

Jubilee Metals Group PLC's (LON:JLP) Leon Coetzer caught up with Proactive London's Andrew Scott after reporting its sixth consecutive six-monthly period of double digit growth - posting a 54% increase in first-half earnings to £12.8mln. The company was also able to boost revenue by 18% to...

16 hours, 19 minutes ago

2 min read